載入中
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
前收盤價
US$1.03
−US$0.08 · -7.21%
盤中時間採用ET。市場資料可能有所延遲。
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
日內區間
目前US$1.03
52週區間
目前US$1.03
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
43
合理估值
情緒
56
多空交錯
風險
66
高風險
動能
16
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
日內區間
目前US$1.03
52週區間
目前US$1.03
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 981.3萬 USD | 949.9萬 USD | 470.4萬 USD | 196.7萬 USD | 181萬 USD |
| 銷售、一般及管理費用 | 627.7萬 USD | 504.8萬 USD | 239.7萬 USD | 245.4萬 USD | 212萬 USD |
| 營業費用 | 1609萬 USD | 1454.7萬 USD | 710.4萬 USD | 443.2萬 USD | 404萬 USD |
| 利息收入 | — | 6.2萬 USD | 7000 USD | 1.1萬 USD | 2.6萬 USD |
| 利息支出 | — | 62.8萬 USD | — | 3000 USD | — |
| 折舊和攤銷 | 4.2萬 USD | 3.6萬 USD | 1.3萬 USD | 2.3萬 USD | 4.2萬 USD |
| 營業利益 | −1609萬 USD | −1454.7萬 USD | −710.4萬 USD | −443.2萬 USD | −404萬 USD |
| 淨利 | −1938.8萬 USD | −2259.7萬 USD | −709.7萬 USD | −443.5萬 USD | −406.7萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
